Seán McNamara of Smith & Williamson LLP, the Liquidator of Osteologix Holdings Plc and Osteologix Limited (both in Liquidation) and Jakob Mosegaard Larsen of Mazanti-Andersen Korsø Jensen, the Liquidator of Osteologix ApS (in Liquidation) (collectively known as “Osteologix” or “the Companies”) have appointed Metis Partners to support the marketing and sale of the intellectual property (“IP”) assets relating to the Companies.
IP ASSET HIGHLIGHTS
- Innovative Pharmaceutical Portfolio
- Extensive International Patent Protection
- Significant Industry Exposure at Leading Conferences
- Potential Patent Licensing Opportunities
This is a unique opportunity to purchase an innovative pharmaceutical patent portfolio, with extensive international coverage.
All offers and requests for more information should be submitted by email directly to Morven Fraser at email@example.com or Nat Baldwin at firstname.lastname@example.org. The deadline for offers has been set at Thursday 28th April 2016 at noon.
An exciting and innovative extensive patent portfolio has been developed by Osteologix, a group of companies which were founded in order to develop pharmaceutical solutions for the treatment and prevention of bone and joint tissue diseases.
The Osteologix patent portfolio had previously been licensed to the Servier Laboratoires, a multi-national pharmaceutical company in order to develop and commercialise the technology.
With significant exposure at industry leading conferences, the Osteologix patent portfolio represents a potentially substantial opportunity for the pharmaceutical industry. Given the unique patents and extensive coverage of these patents, there are also significant monetisation opportunities through worldwide licensing or infringement actions.
PATENT PORTFOLIO OVERVIEW
The Osteologix patent portfolio comprises 5 patent families, all of which include numerous granted patents with worldwide coverage, including the US, Europe, Japan, China, and Australia.
In addition to offering solutions for osteoporosis, the Osteologix technology has been explored for disorders where bone and cartilage metabolism is affected, including osteoarthritis, metastatic bone disease, hyperparathyroidism-associated bone disease, secondary osteoporosis and renal disease
There has been demonstrated interest in the patent portfolio from worldwide organisations, with companies such as Servier Laboratoires, Nutraceutical Corporation, Astra Tech AB, Merckle GMGH, and Lacer SA citing the Osteologix patents within their own patent portfolios.
IP ASSETS FOR SALE
- Extensive international patent portfolio
- Goodwill in the brand and reputation
- Unregistered rights in the Osteologix trade mark